Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients

Clinical TransplantationVolume 37, Issue 4 e14929 LETTER TO THE EDITOR Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients David C. Sabatino, David C. Sabatino orcid.org/0000-0002-4237-7960 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorJessica Hedvat, Jessica Hedvat orcid.org/0000-0001-8161-479X NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorDavid M. Salerno, David M. Salerno orcid.org/0000-0002-5450-3995 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorMarcus R. Pereira, Marcus R. Pereira orcid.org/0000-0002-9214-9122 Columbia University Vagelos College of Physicians and Surgeons, Department of Medicine, New York, New York, USASearch for more papers by this authorNicholas W. Lange, Corresponding Author Nicholas W. Lange [email protected] orcid.org/0000-0003-2520-6657 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USA Correspondence Nicholas W. Lange, PharmD, 622 West 168th Street, VC-Basement, New York, NY 10032, USA. Email: [email protected]Search for more papers by this author David C. Sabatino, David C. Sabatino orcid.org/0000-0002-4237-7960 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorJessica Hedvat, Jessica Hedvat orcid.org/0000-0001-8161-479X NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorDavid M. Salerno, David M. Salerno orcid.org/0000-0002-5450-3995 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USASearch for more papers by this authorMarcus R. Pereira, Marcus R. Pereira orcid.org/0000-0002-9214-9122 Columbia University Vagelos College of Physicians and Surgeons, Department of Medicine, New York, New York, USASearch for more papers by this authorNicholas W. Lange, Corresponding Author Nicholas W. Lange [email protected] orcid.org/0000-0003-2520-6657 NewYork-Presbyterian Hospital, Department of Pharmacy, New York, New York, USA Correspondence Nicholas W. Lange, PharmD, 622 West 168th Street, VC-Basement, New York, NY 10032, USA. Email: [email protected]Search for more papers by this author First published: 05 February 2023 https://doi.org/10.1111/ctr.14929Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1 Maribavir (Livtencity). [package insert]. Takeda pharmaceuticals; Lexington (MA): 2021. 2Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2021; 75(4): 690-701. doi:10.1093/cid/ciab988 3Sabatino DC, Hedvat J, Salerno DM, Lange NW. Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients. Transpl Infect Dis. 2022; 24(4):e13869. doi:10.1111/tid.13869 Volume37, Issue4April 2023e14929 ReferencesRelatedInformation